

CHNA

Loncar China BioPharma ETF

Analyst Report

CHNA tracks a tier-weighted index of companies directly involved in the growth of China's pharmaceutical and biotech industry.

ESG Themes and Scores

4.78/10

ESG Rate

20.36%

Global Percentile

40.53%

Peer Percentile

Performance Data

	CHNA	ETF Database Category Average	Factset Segment Average
1 Month	-10.15%	-8.59%	-10.15%
3 Month	-13.44%	-9.98%	-13.44%
YTD Return	-26.86%	-9.55%	-26.86%
1 Year Return	-6.60%	-7.80%	-6.60%
3 Year Return	-20.40%	-3.50%	-20.40%
5 Year Return	-6.85%	0.63%	-6.85%

Top 5 Holdings

Symbol	Holding	% Assets
2359	WuXi AppTec Co., Ltd. Class H	3.19%
LEGN	Legend Biotech Corp. Sponsored ADR	3.07%
6660	AIM Vaccine Co., Ltd. Class H	2.90%
1099	Sinopharm Group Co., Ltd. Class H	2.68%
6826	Shanghai Haohai Biological Technology Co., Ltd. Class H	2.58%

Vitals

Issuer	Exchange Traded Concepts
Brand	Loncar
Structure	ETF
Expense Ratio	0.79%
Inception	Aug 14, 2018
Index Tracked	Loncar China BioPharma Index

ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Blend
Region (General)	Emerging Asia Pacific
Region (Specific)	China

FactSet Classifications

Segment	Equity: China Pharma, Biotech & Life Sciences
Category	Sector
Focus	Health Care
Niche	Pharma, Biotech & Life Sciences
Strategy	Equal
Weighting	Tiered

